The U.S. Senate Banking Committee will not have any markup hearings on market structure legislation defining how federal regulators can oversee the industry until next year, punting on a hoped-for ...

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...

Creating simple data classes in Java traditionally required substantial boilerplate code. Consider how we would represent Java’s mascots, Duke and Juggy: public class JavaMascot { private final String ...

A controlled test compared three nearly identical pages: one with strong schema, one with poor schema, and one with none. Only the page with well-implemented schema appeared in an AI Overview and ...

Abstract: To combine the strengths of Gaussian and non-Gaussian latent variable models, a novel information fusion strategy has recently been proposed under the deep learning framework. Although ...

Community driven content discussing all aspects of software development from DevOps to design patterns. The AWS Certified Data Engineer Associate exam validates your ability to design, build, and ...

The Eclipse Foundation's Jakarta EE Working Group has released Jakarta EE 11, the latest version of its enterprise Java platform, marking a significant step in modernizing enterprise Java development ...

A flaw in code for handling Parquet, Apache’s open-source columnar data file format, allows attackers to run arbitrary code on vulnerable instances. The vulnerability, tracked as CVE-2025-30065, is a ...

Graduate School of Pharmaceutical Sciences, Keio University, Minato-ku, Tokyo 105-8512, Japan Molecular and Cellular Epigenetics Laboratory, Graduate School of Medical Life Science, Yokohama City ...

Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, ...